

# Multi-ancestry transcriptome-wide association analyses yield insights into tobacco use biology and drug repurposing

Received: 25 October 2021

Accepted: 8 December 2022

Published online: 26 January 2023

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Most transcriptome-wide association studies (TWASs) so far focus on European ancestry and lack diversity. To overcome this limitation, we aggregated genome-wide association study (GWAS) summary statistics, whole-genome sequences and expression quantitative trait locus (eQTL) data from diverse ancestries. We developed a new approach, TESLA (multi-ancestry integrative study using an optimal linear combination of association statistics), to integrate an eQTL dataset with a multi-ancestry GWAS. By exploiting shared phenotypic effects between ancestries and accommodating potential effect heterogeneities, TESLA improves power over other TWAS methods. When applied to tobacco use phenotypes, TESLA identified 273 new genes, up to 55% more compared with alternative TWAS methods. These hits and subsequent fine mapping using TESLA point to target genes with biological relevance. In silico drug-repurposing analyses highlight several drugs with known efficacy, including dextromethorphan and galantamine, and new drugs such as muscle relaxants that may be repurposed for treating nicotine addiction.


Cigarette smoking is a major heritable risk factor for human diseases. The availability of large datasets has enabled a breakthrough in the genetics of smoking addiction, with >400 loci discovered to date<sup>1</sup>. Although some of these associations point to genes and pathways of known biological importance, including the nicotinic receptor and dopaminergic signaling pathway genes<sup>1</sup>, the underlying mechanisms for most of the identified loci are unknown. On top of this, the genetic architecture of tobacco use outside of European populations remains understudied. In the present study, we combined GWAS datasets totaling 1.3 million individuals: 1.2 million from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) and 150,000 diverse ancestries from the Trans-Omics Precision Medicine (TOPMed)<sup>2</sup> to further empower gene discovery and elucidate the genetic architecture of smoking behavior.

Dissecting the mechanisms of GWAS hits for tobacco use is crucial to understand the etiology of nicotine addiction and related disease outcomes. TWAS approaches (for example, FUSION<sup>3</sup>, TIGAR<sup>4</sup>, PrediXcan<sup>5</sup> and UTMOST<sup>6</sup>) use eQTLs to predict gene expression levels in silico, which the method then uses to identify genes associated with

the phenotype of interest. Various TWAS methods have been widely applied to different complex traits to understand the functional consequences of regulatory variations<sup>7–9</sup>.

TWAS in its original form requires GWAS and eQTL data to be from matched ancestries. Direct integration of eQTLs with GWAS data from nonmatched ancestries (for example, integrating European-derived eQTLs with non-European GWASs) was shown to have suboptimal power<sup>10</sup>. The results may also be difficult to interpret because causal variants underlying GWAS hits or eQTLs may differ between ancestries. An alternative strategy is to use ancestry-matched eQTL data from disease-relevant tissues and perform TWAS separately for each ancestry (which we call MATCH-TWAS). MATCH-TWAS may be difficult or even impossible to implement in practice because eQTL data may not be broadly available for disease-relevant tissues in non-European ancestries. In addition, because most causal variants have been observed to be consistent across ancestries<sup>11–13</sup>, MATCH-TWAS can suffer from substantial power loss by using only the GWAS data from the matched ancestry, due simply to smaller sample size. Another possible strategy is to ignore ancestral differences and perform TWAS using GWAS fixed

✉ e-mail: [bjiang@phs.psu.edu](mailto:bjiang@phs.psu.edu); [vrieze@umn.edu](mailto:vrieze@umn.edu); [dajiang.liu@psu.edu](mailto:dajiang.liu@psu.edu)



**Fig. 1 | Schematic description of the TESLA method.** TESLA uses meta-regression to model phenotypic effect estimates as functions of the PCs of genome-wide allele frequencies from each cohort. For a given gene expression prediction model generated from an eQTL dataset, we use TESLA to more

accurately estimate phenotypic effects, then use them to perform TWASs and attain optimal power. We also performed fine mapping and enrichment analysis using the TESLA results (which we call eTESLA).

**Table 1 | TESLA identified substantially more loci and new loci than FE-TWASs, RE-TWASs and EURO-TWASs using GTEx data and PrediXcan weights**

Genes identified across all the tissues				
Trait	TESLA	FE-TWAS	RE-TWAS	EURO-TWAS
Smklnit	3,066 (908, 193)	2,916 (852, 168)	218 (84, 12)	2,729 (795, 132)
SmkCes	476 (155, 19)	414 (136, 16)	33 (19, 4)	428 (144, 16)
CigDay	840 (276, 46)	793 (248, 29)	482 (143, 31)	793 (229, 26)
Agelnit	93 (50, 15)	64 (38, 8)	8 (7, 3)	29 (21, 2)
Total	4475 (1,389, 273)	4187 (1,274, 221)	741 (147, 50)	3979 (1,189, 176)

Genes with two-sided TWAS  $P$  values  $< 2.5 \times 10^{-6}$  were deemed statistically significant. A gene $\times$ trait association was considered new if it was  $> 1 \times 10^6$  bp away from previously reported GWAS hits. The number of gene $\times$ trait associations, the number of unique gene $\times$ trait associations (that is, the gene $\times$ trait association that appears in multiple tissues are counted only once) and new associations are shown for each TWAS method. The numbers in parentheses are unique gene and new gene counts, respectively

effect (FE) or random effect (RE) meta-analysis results combining different ancestries (FE-TWAS and RE-TWAS). FE-TWAS and RE-TWAS do not fully leverage ancestral differences in phenotypic effect sizes and linkage equilibrium (LD) patterns, which also leads to suboptimal power.

Given the lack of sizable eQTL datasets from disease-relevant tissues in a matched ancestry, it is important to develop methods to optimally integrate an existing eQTL dataset from a given ancestry (European or any ancestry) in a multi-ancestry meta-analysis.


To achieve this goal, we developed a new method, TESLA, which exploits shared phenotypic effects across ancestries and accommodates between-ancestry genetic effects, and consistently improves power over existing methods. We identify many more gene-level associations than alternative methods, such as MATCH-TWAS and FE-TWAS. We also performed fine mapping, enrichment and drug-repurposing analyses for TWAS hits to learn new biology and gain clinical insights related to tobacco use phenotypes.

## Results

### Method overview

For all presentations, we call the genetic effects on GWAS phenotypes ‘phenotypic effects’ and the effect of gene expression the ‘eQTL effect’. TWAS was originally developed to integrate eQTL and GWAS datasets derived from matched ancestries<sup>5</sup>. Specifically, it first builds gene expression prediction models using eQTL datasets that measure both gene expression levels and genotypes and obtains weights on eQTL SNPs ( $w_j$ ). The eQTL weights are then used to calculate a weighted sum of phenotypic effect estimates (which we denote as  $b_j$  for the effect of variant  $j$ ) for gene-level association tests. When adapting TWAS to integrate European eQTL data with non-European GWAS data, power loss was observed empirically<sup>10</sup>, but the theoretical reason behind the power loss was not well established.

In the present study, we propose a proportionality condition under which trans-ancestry TWAS attains its optimal power. Specifically, the proportionality condition states that TWAS has optimal power if the phenotypic effects and eQTL weights from the gene expression prediction model are proportional to each other. This condition is satisfied when the eQTL SNPs influence phenotypes via their regulatory effects,



**Fig. 2 | Manhattan plot for multi-tissue TESLA results using GTEx for CigDay phenotype.** For each chromosome, we labeled the fine-mapped genes with posterior inclusion probability (PIP) > 0.9 (with  $P < 2.5 \times 10^{-6}$ ). If more than ten genes were significant for a chromosome, only the top ten genes were labeled. The Manhattan plot for other traits can be found in Supplementary Fig. 2.


All  $P$  values are two sided. We have now labeled the fine-mapped genes with PIP > 0.9 in the Manhattan plot. For smoking initiation trait, there are a large number of fine-mapped signals, so we labeled only ten genes per chromosome with the largest PIP values.

that is,  $\text{SNP}_j \xrightarrow{w_j} \text{Expression} \xrightarrow{c} \text{Phenotype}$ , where  $w_j$  is the eQTL effect of  $\text{SNP}_j$  from the gene expression prediction model and  $c$  is the effect of genetically regulated gene expressions on the phenotypes. The phenotypic effect of variant  $j$  satisfies  $\beta_j = w_j c$ . When the eQTL and GWAS data come from the same ancestry and the phenotypic and eQTL effect heterogeneities between studies are modest, the proportionality condition is expected to hold. However, when integrating non-European GWASs with European eQTL datasets, this proportionality condition can be violated and the power for TWASs is suboptimal because the set of causal variants and their phenotypic effects may differ across different ancestries. Motivated by this proportionality condition, we developed an improved TWAS method, TESLA, that optimally integrates a given eQTL dataset with a multi-ancestry GWAS. TESLA consists of three key steps.

First, TESLA models phenotypic effects across ancestries using meta-regression, which takes phenotypic effect estimates, standard deviations and genome-wide allele frequency principal components (PCs, as a proxy for ancestry) as input. We estimate ancestry using genetic PC analysis on per-study allele frequencies, although other methods may also be used. When no PC is included, the model

is equivalent to a fixed-effects meta-analysis; when one or more PCs are included, the meta-regression coefficients quantify the extent of SNP effect heterogeneity as a function of ancestry. For example, in the present study, the first PC separates cohorts of individuals with recent African–American ancestries (Supplementary Fig. 4). The regression coefficient for the first PC will estimate how much the phenotypic effect varies between samples of African and non-African ancestry. This model jointly analyzes different ancestries, which maximizes the sample size and improves the phenotypic effect estimates. To account for the unknown extent of phenotypic effect heterogeneities, we fit multiple different meta-regression models with varying numbers of PCs. The method synthesizes the phenotypic effect estimates from different meta-regression models in the third step for TWASs.

Next, for each fitted model, we estimate phenotypic effects in the ancestry that match the eQTL dataset. For cohorts from ancestries that do not match the eQTL dataset, their phenotypic effect will be projected to allele frequency PCs of the eQTL dataset and then meta-analyzed with other cohorts. The resulting estimates benefit from the contribution of cohorts of all ancestries and satisfy the proportionality condition, as long as the phenotypic effects are mediated by the



**Fig. 3 | Key addiction-related pathways are ubiquitously enriched with TESLA hits in multiple brain tissues.** We displayed TESLA enrichment  $P$  values (two sided) across 13 GTEx brain tissues using radar plots. **a, b**, The enrichment of TESLA hits for cigarettes per day for the dopaminergic synapse pathways (**a**) and the behavioral response to nicotine pathways (**b**). Gridlines in the radar plots

indicate different levels of statistical significance. Each spoke represents a brain tissue and the length of the spoke represents the  $-\log_{10}(P)$  of enrichment. Brain tissues with significant enrichment  $P$  values after multiple testing corrections are shown in red. CC, cellular component; BP, biological process.

genetically regulated gene expressions and effect heterogeneity in the same ancestry is modest. The performance of TWASs using the eQTL weights and estimated phenotypic effects in the matched ancestry thus yields optimal power.

Finally, TESLA combines the TWAS results based on multiple meta-regression models using a minimal  $P$ -value method to attain robust results. We also assessed whether TESLA hits are enriched in pathways or tissues and identified candidate drugs that may be repurposed for smoking cessation. We provide details in Methods and Supplementary Text.

We perform extensive simulation to evaluate the proposed method and compare them with FE-TWASs, RE-TWASs and EURO-TWASs using meta-analysis results from METASOFT (Code availability). We show that TESLA consistently outperforms or performs competitively compared with other methods across all scenarios (Supplementary Text and Supplementary Tables 1 and 2). In fact, TESLA is the only method that performs consistently well. Given that the genetic effects are often unknown in practice, TESLA is a clear favorite in real applications.

### TESLA improves gene discovery in diverse ancestries


We applied TESLA to summary-level association statistics derived from 61 cohorts in GSCAN and TOPMed studies of 4 smoking traits including smoking initiation (SmkInit, binary trait of smoker versus nonsmoker), cigarettes per day (CigDay, continuous outcome), smoking cessation (SmkCes, binary outcome comparing current versus former smokers) and age of smoking initiation (AgeInit, continuous outcome of the age of starting regular smoking) (Supplementary Table 3). Details of phenotype definitions can be found in Methods and Supplementary Text. PrediXcan weights of 48 tissues from samples of European ancestry in GTEx (v.7) (Genotype-Tissue Expression) were used. TESLA was applied to analyze gene-phenotype associations in each tissue separately. All statistical tests that we performed and the reported  $P$  values are two sided, unless stated otherwise. Tissue-specific TESLA results were also combined using the Cauchy combination test<sup>14</sup> to obtain a  $P$  value of a

multi-tissue TWAS for each gene. A schematic description of the TESLA analysis flow is shown in Fig. 1.

TESLA results produced well-calibrated genomic control values (Supplementary Fig. 1) in each GTEx tissue and phenotype. A total of 4,475 gene  $\times$  trait associations (across 48 tissues, 1,389 unique genes in total) of 4 smoking traits were identified by TESLA with  $P$  values  $< 2.5 \times 10^{-6}$  (Bonferroni's threshold for testing up to 20,000 expressed genes), which was 6.9%, 50.4% and 12.5% more than FE-TWAS, RE-TWAS and EURO-TWAS, respectively (Table 1, Fig. 2 and Supplementary Figs. 2 and 3). Although 87% of the GWAS samples were of European ancestry, we still noted considerable improvement in power from TESLA, which corroborated the simulation results. Among these results, 783 gene  $\times$  trait associations (384 unique genes) were identified in 13 brain tissues, including the amygdala, anterior cingulate cortex, caudate, cerebellar hemisphere, cerebellum, cortex, frontal cortex, hippocampus, hypothalamus, nucleus accumbens, putamen, brain spinal cord (cervical C1) and substantia nigra (Supplementary Table 4).

Among the TESLA-identified genes, 15, 193, 19 and 46 were new for AgeInit, SmkInit, SmkCes and CigDay, respectively, which are  $> 1 \times 10^6$  base pairs (bp) away from known GWAS sentinel variants (Supplementary Table 5). The number of new genes identified by TESLA was also 23.5% and 55.1% more than FE-TWAS and EURO-TWAS, respectively. We also counted the number of new loci where we considered genes within  $1 \times 10^6$  bp of each other to be the same locus. A similar advantage remains where the number of new loci identified by TESLA is 20.5% and 32.5% more than FE-TWASs and EURO-TWASs, respectively. The improvements over FE-TWAS showcase the advantage of the TESLA method, whereas the advantage over EURO-TWAS is probably attributable to the addition of non-European samples. The advantage of TESLA was maintained when a more stringent  $P$ -value threshold was used (that is,  $5.0 \times 10^{-8}$ , Bonferroni's threshold for testing 20,000 genes among 48 tissues) (Supplementary Table 6).

The number of significant associations in each tissue was influenced by both the tissue relevance for the trait and the sample size of the eQTL dataset. Although brain tissues are known to be involved in



**Fig. 4 | Different brain tissues are enriched with distinct pathways.** We used REVIGO to reduce redundant GO terms and facilitate the visualization of enrichment results. We highlighted three brain regions (that is, cortex, substantia nigra and cerebellum) with distinct patterns of enrichment. For brain cortex,

one GO term (relaxation of smooth muscle) accounts for 98.3% of the pathways enriched with TWAS hits, whereas, for substantia nigra and cerebellum, a diverse set of GO terms was enriched with TWAS hits. The brain figures are generated by R package ggseg<sup>43</sup>.

tobacco use phenotypes, we did not observe an increased number of associated genes in brain tissues, possibly because the small sample sizes of brain tissue eQTL datasets lead to limited power for predicting gene expression in silico. On the other hand, we typically found a larger number of gene  $\times$  trait associations in tissues with larger eQTL sample sizes, with TWASs in whole blood yielding the largest number of associations (Supplementary Fig. 3).

Similar patterns were observed for TESLA analysis with nucleus accumbens eQTL data from the Lieber Institute for Brain Development (LIBD) Human Brain Repository, which contains a higher representation of non-European ancestry ( $n = 198$ ; 53% of European and 47% with African ancestry) than GTEx ( $n = 114$  for nucleus accumbens; overall 15% non-European ancestry). As the sample size of non-European ancestry GWASs is relatively small (AgelNit  $n = 11,626$ , CigDay  $n = 12,379$ , SmkCes  $n = 14,293$ , SmkInit  $n = 22,693$ ), the number of gene  $\times$  trait associations identified using African-American eQTL data is small, but a significant portion is replicated in the TWAS using European eQTLs (Supplementary Table 7). The advantage of TESLA over alternative TWAS methods widened even more using the African ancestry eQTL dataset, because the fraction of non-African ancestry GWAS samples is large. Across 4

smoking traits, TESLA identified 122 genes, which was 91% more than FE-TWAS (64 significant gene associations), the second-best method. On the other hand, AFR-TWAS that uses ancestry-matched African ancestry eQTL and GWAS data yielded much smaller numbers of genes, because only a small fraction of GWAS cohorts was of African ancestry. This showed that conducting TWASs using only ancestry-matched GWAS and eQTL datasets cannot overcome sample size limitations and thus they remain severely underpowered (Supplementary Table 8).

Based on TESLA results, we quantified the extent of phenotypic effect heterogeneity based on the models that yield minimal  $P$  values and show that 77% of the genes have homogeneous effects across ancestries. (Supplementary Text, Supplementary Figs. 4 and 5 and Supplementary Table 9). We also performed fine-mapping analysis and identified a number of genes with biological relevance (Supplementary Text, Supplementary Fig. 6 and Supplementary Table 10).

#### Enrichment analysis highlighted key pathways

We used gene ontology (GO) enrichment analysis to find pathways, tissues and cell types relevant to tobacco use (Supplementary Table 11). Our enrichment analysis is based on the same idea as

**Table 2 | Top drugs identified using enrichment analysis**

Drug name	Indication	Smoking trait	Minimal <i>P</i> value and tissue types <sup>a</sup>	MAGMA <sup>b</sup>	Reference <sup>c</sup>
<b>Putative drug targets that may be repurposed for smoking cessation</b>					
Dextromethorphan	Coughing	CigDay	<b><math>3.3 \times 10^{-39}</math> (caudate basal ganglia)</b>	$1.0 \times 10^{-4}$	32,41
		SmkInit	<b><math>9.2 \times 10^{-15}</math> (brain spinal cord cervical C1)</b>	0.36	
		SmkCes	$2.8 \times 10^{-4}$ (brain spinal cord cervical C1)	<b><math>9.2 \times 10^{-9}</math></b>	
Ganaxolone	Seizure disorders (investigated)	CigDay	<b><math>1.3 \times 10^{-9}</math> (substantia nigra)</b>	0.05	33
		SmkInit	$3.5 \times 10^{-3}$ (cerebellum)	0.66	
		SmkCes	0.08 (caudate basal ganglia)	0.02	
Galantamine	Alzheimer's disease	CigDay	<b><math>4.2 \times 10^{-73}</math> (substantia nigra)</b>	<b><math>7.7 \times 10^{-14}</math></b>	34,42
		SmkInit	$1.3 \times 10^{-4}$ (brain spinal cord cervical C1)	$4.3 \times 10^{-3}$	
		SmkCes	0.020 (cortex)	<b><math>3.4 \times 10^{-9}</math></b>	
<b>Clinical drugs identified</b>					
Nicotine	Smoking cessation	CigDay	<b><math>4.2 \times 10^{-71}</math> (substantia nigra)</b>	<b><math>4.3 \times 10^{-17}</math></b>	First-line therapy
		SmkInit	$1.3 \times 10^{-5}$ (hypothalamus)	0.01	
		SmkCes	0.03 (amygdala)	<b><math>5.8 \times 10^{-11}</math></b>	
Varenicline		CigDay	<b><math>4.8 \times 10^{-26}</math> (frontal cortex BA9)</b>	<b><math>5.6 \times 10^{-6}</math></b>	First-line therapy
		SmkInit	<b><math>9.2 \times 10^{-15}</math> (brain spinal cord cervical C1)</b>	$5.9 \times 10^{-3}$	
		SmkCes	$2.8 \times 10^{-4}$ (brain spinal cord cervical C1)	<b><math>8.2 \times 10^{-9}</math></b>	
Bupropion		CigDay	<b><math>9.0 \times 10^{-19}</math> (brain spinal cord cervical C1)</b>	0.62	First-line therapy
		SmkInit	<b><math>9.2 \times 10^{-15}</math> (brain spinal cord cervical C1)</b>	0.92	
		SmkCes	$2.8 \times 10^{-4}$ (brain spinal cord cervical C1)	0.05	
Cytisine		CigDay	<b><math>3.9 \times 10^{-132}</math> (frontal cortex BA9)</b>	<b><math>5.6 \times 10^{-6}</math></b>	Second-line therapy
		SmkInit	<b><math>9.2 \times 10^{-15}</math> (brain spinal cord cervical C1)</b>	$5.9 \times 10^{-3}$	
		SmkCes	$2.8 \times 10^{-4}$ (brain spinal cord cervical C1)	<b><math>8.2 \times 10^{-9}</math></b>	
Anxiolytic drugs (butalbital) <sup>d</sup>		CigDay	<b><math>4.8 \times 10^{-132}</math> (frontal cortex BA9)</b>	$1.1 \times 10^{-3}$	Second-line therapy
		SmkInit	$4.9 \times 10^{-5}$ (cerebellar hemisphere)	$7.3 \times 10^{-3}$	
		SmkCes	$1.1 \times 10^{-3}$ (caudate basal ganglia)	0.33	

Drug enrichment analysis of TESLA results implicates drugs with biological relevance and drugs that are being clinically evaluated. We created gene sets of drug target genes and tested whether these gene sets were enriched with TESLA hits. The most significant TESLA *P* values for enrichment analysis are shown and, as a comparison and validation, we also show enrichment analysis based on MAGMA for implicated drugs. Full results are available in Supplementary Table 14. All *P* values are two sided. <sup>a</sup>The minimal *P* value in 13 brain tissues; significance Bonferroni's corrected *P* values that are under 5% threshold and labeled bold. <sup>b</sup>MAGMA using the GWAS signals; significant *P* values after Bonferroni's correction are labeled bold. <sup>c</sup>References where the candidate drugs were discussed. Preliminary clinical/basic evidence/references support the drug repositioning. <sup>d</sup>Complete enrichment results for anxiolytic drugs are shown in Supplementary Table 14.

GWAS-based pathway analysis tools, such as MAGMA<sup>15</sup>, which leverage weighted regression to assess whether a given pathway is enriched with TWAS hits from a given tissue<sup>16</sup>. First, we identified a number of key pathways with known biological relevance to addiction that are ubiquitously enriched in multiple tissues. These pathways include neuromuscular synaptic transmission (GO:0007274), neurotransmitter catabolic process (GO:0042135), negative regulation of synaptic transmission, GABAergic (GO:0032229), Lewy body (GO:0097413) and dopaminergic synapse (GO:0098691) (Fig. 3a). Importantly, many tobacco-related pathways are consistently ranked among the top pathways (family-wise error rate (FWER) < 0.05) in the cerebellum, including neurotransmitter catabolic process (GO:0042135) for CigDay ( $P = 9.5 \times 10^{-11}$ ), dopaminergic synapse (GO:0098691) for SmkInit ( $P = 1.2 \times 10^{-9}$ ) and behavioral response to nicotine (GO:0035095) for CigDay ( $P = 2.3 \times 10^{-14}$ ). This finding is consistent with increasing evidence showing that cerebellum

functions extend beyond motor control and involve rewarding and addictive behaviors<sup>17–22</sup>.

On the other hand, for most pathways, the enrichment patterns differ between traits and tissues, which implicated potentially different genetic architectures (Fig. 3b). To reduce the dimension of the data and reveal underlying biology, we clustered GO items using the REVIGO method<sup>23</sup> (Code availability and Supplementary Fig. 7). For CigDay, the only dominant pathway category enriched with TWAS hits in cortex is 'relaxation of smooth muscle' (GO:0044557,  $P = 3.4 \times 10^{-7}$ , with weight = 98.3%), whereas there are more diverse GO items in substantia nigra, an important brain tissue for reward. The top GO terms enriched with TESLA hits include: 'positive regulation of fatty acid transport' (weight = 31.3%), 'epithelial cell morphogenesis' (weight = 31.1%), 'negative regulation of feeding behavior' (weight = 15.5%) and 'sensory of touch' (weight = 6.7%) (Fig. 4). The top

GO terms have been implicated in substance use and addictive behaviors. For example, poly(unsaturated fatty acids) were known to influence psychiatric outcomes among drug users and food supplements for poly(unsaturated fatty acids) have been used to stabilize aggressive behaviors<sup>24</sup>. It is interesting that smoking is also known to reduce stress and have self-medication effects. In addition, the enriched GO term ‘negative regulation of feeding behavior’ is corroborated by many smoking-associated loci. These loci were implicated in feeding behavior due to their functions in reward processing<sup>25</sup>. Results from MAGMA enrichment analyses using samples of European ancestry were included as a comparison (Supplementary Table 12). Top hits from MAGMA remain significant in TESLA and show up in multiple tissues, whereas hits that are only significant in TESLA tend to be more tissue specific.

Finally, we incorporated single-cell RNA-sequencing (scRNA-seq) data from neurons in the mouse central nervous system to prioritize specific cell types related to tobacco use phenotypes<sup>26</sup>. We created cell-type-specific gene sets that consist of the top 10% most highly expressed genes specific to each cell type and tested whether they are enriched with TESLA hits (Supplementary Fig. 8 and Supplementary Table 13). We highlighted cholinergic and monoaminergic neurons ( $P = 4.9 \times 10^{-6}$ , FEWR < 0.01), as well as glutamatergic neuroblasts ( $P = 6.1 \times 10^{-6}$ , FEWR < 0.01), as relevant cell types for CigDay in the cerebellum (Supplementary Fig. 8), which corroborated human brain transcriptomic data.

### Enrichment analysis identified drugs for repurposing

We created genes sets for targeted pathways of each drug in DrugBank<sup>27</sup> and examined whether these drug target pathways were enriched with TESLA hits in 13 brain tissues from GTEx. We identified 102 putative drugs pathways under stringent Bonferroni’s threshold for testing 1,642 drugs ( $7.9 \times 10^{-7}$ ) (Supplementary Table 14). As confirmation, we also included enrichment analysis based on MAGMA, a gene-based method that aggregates phenotype association results without incorporating eQTLs, using samples of European ancestry. Our results pointed to drugs with putative or known relevance to smoking cessation and suggested new drug classes that may be repurposed for treatment of smoking cessation (Table 2).

First, as a positive control and confirmation of the validity of our approach, our enrichment analysis identified approved drugs, including varenicline, bupropion and cytisine, which are used as first- or second-line therapies for smoking cessation<sup>28–31</sup>.

Second, TESLA enrichment pointed to drugs with putative smoking cessation effects, which are being evaluated in clinical trials. For example, the target pathway of dextromethorphan<sup>32</sup>, a drug originally used to treat cough, is enriched with CigDay loci in anterior cingulate cortex BA24 ( $P = 3.28 \times 10^{-31}$ , FEWR < 0.01), caudate basal ganglia ( $P = 1.17 \times 10^{-39}$ , FEWR < 0.01) and cerebellum ( $P = 7.4 \times 10^{-39}$ , FEWR < 0.01). The drug target pathway for ganaxolone<sup>33</sup>, a drug used for seizure disorders, is enriched with CigDay loci in hippocampus ( $P = 2.2 \times 10^{-5}$ , FEWR < 0.01) and substantia nigra ( $P = 1.1 \times 10^{-9}$ , FEWR < 0.01).

Enrichment analysis also identified potential drugs for treating smoking addiction, which are supported by preliminary clinical evidence. For example, galantamine, a Food and Drug Administration-approved medication for the treatment of cognitive deficits associated with Alzheimer’s disease, increases synaptic acetylcholine levels by inhibiting acetylcholinesterase, an enzyme that breaks down acetylcholine. Galantamine also directly stimulates  $\alpha 7$ - and  $\alpha 4\beta 2$ -nicotinic acetylcholine receptors (nAChRs) via its positive allosteric modulator actions<sup>34</sup>.

In addition to individual drugs, we also evaluated the potential of drug classes that can be repurposed for smoking cessation. To do so, we grouped all the identified drugs into 15 categories based on their indications (see Supplementary Text). The top drug group enriched with CigDay hits was muscle relaxants, which have established relevance to

smoking. For example,  $\gamma$ -aminobutyric acid (GABA)  $\beta$ -agonist baclofen was shown to ameliorate nicotine- and drug-induced behavior in animals and humans. This could be due to their shared targets of nAChR pathways with smoking addiction. The other two largest drug groups were for the treatment of mental disorders and neurological drugs (Supplementary Fig. 9).

### Discussion

In the present study, we conducted a multi-ancestry TWAS using GWASs and whole-genome sequence data from 1.3 million individuals. Our TWAS results highlighted shared mechanisms with other substance use behaviors (for example, cocaine addiction) and psychiatric phenotypes (for example, pain sensitivity, depression and anxiety). Leveraging shared disease pathways, we identified drugs that may be repurposed for smoking cessation treatment, including dextromethorphan and galantamine, which are already being assessed in clinical trials. Given the tremendous public health burden that continues to be incurred by smoking, repurposing drugs for smoking cessation is extremely valuable, because it offers a potentially quicker and more cost-effective route to treatment than the development of new therapeutic targets.

Our work also made important methodological contributions. TESLA showed robust performance over other methods across different genetic architectures, which makes it a desirable choice in practice, because the true phenotypic effects across ancestries are unknown. TESLA improves power because it jointly analyzes samples from multiple ancestries, maximizes sample sizes and accommodates between-ancestry heterogeneities. The magnitude of increased power depends on the genetic architecture of the traits across ancestries. TESLA has the largest advantage when causal variants are shared between ancestries but have heterogeneous effects. Its performance is comparable to other well-performing methods when the effects are unique to European ancestry or homogeneous across ancestry groups. Importantly, the power improvement of TESLA over alternative methods tends to increase as a larger fraction of non-European samples is included. This ensures that TESLA will be even more useful because genetic studies are expanding to non-European populations, as part of the biomedical research community’s vision for precision health using genomics<sup>35</sup>.

TESLA uses allele frequency PCs to capture cohort ancestry differences<sup>36</sup> (Supplementary Fig. 4), because cohorts from different ancestries show systematic differences in allele frequencies. Similar to genotype PCs<sup>37</sup>, allele frequency PCs can also separate different ancestral groups. For example, the first allele frequency PC separates cohorts of individuals with recent African ancestries from those with other ancestries. As a rule of thumb, the number of PCs used could be determined by the number of relatively distinct ancestral groups of participating studies minus one, to yield sufficient degrees of freedom to separate different major ancestral groups. In our evaluations, we used three PCs, which is consistent with other applications of meta-regression models in multi-ancestry studies<sup>36</sup>. In our simulation study, we varied the number of PCs between two and four and the relative performance remained very similar.

TESLA is optimal when the phenotypic effects are mediated by the eQTL effects. When there are residual genetic effects of eQTL SNPs that influence phenotypes (for example, due to the LD between eQTL SNPs and other causal variants in the region), methods such as variance component (VC)-TWAS<sup>38</sup> would be a useful complementary approach. VC-TWAS, in its original form, applies to individual-level data from a single study or summary association statistics. It does not accommodate multiple sources of input. A straightforward approach is to apply VC-TWAS to meta-analysis results. Given that VC-TWAS is an extension of the sequence kernel association test (SKAT)<sup>39</sup>, another possibility is to extend VC-TWAS in the same way as het-meta-SKAT<sup>39</sup>, which assumes that genetic effects are heterogeneous. These extensions may not be optimal, because they do not properly consider genetic effect

heterogeneities across ancestries. It would be an important future research area to develop optimal strategies to integrate VC-TWAS into trans-ancestry genetic studies.

Although TESLA optimizes the power for TWASs using existing eQTL datasets, it does not take away the need to generate eQTL datasets from non-European populations. The ancestry of the eQTL dataset strongly influences the interpretation of TESLA results. When a European eQTL dataset is used, TESLA identifies target genes specific to European ancestry. Therefore, if a genetic variant has heterogeneous effects, meta-regression will put the most weight over cohorts of European ancestry and less weight on cohorts from non-European ancestry. Similarly, when an eQTL dataset of African ancestry is used (for example, nucleus accumbens from the LIBD dataset), TESLA identifies target genes in African ancestries and cohorts with individuals of African ancestries would contribute the most to meta-analysis. As additional non-European eQTL datasets are generated, TESLA will become even more useful to understand the impact of noncoding variants in non-European populations.

In summary, our study represents an attempt to extend GWASs and TWASs of tobacco use to non-European ancestries. The gene discoveries deepen our understanding of the etiology of tobacco use phenotypes and implicate translational applications. The methodology is broadly useful for next-generation trans-ancestry genetic studies of complex diseases and address critical challenges for multi-ancestry TWASs<sup>40</sup>. TESLA will further improve power over existing methods as more non-European GWASs and eQTL datasets are generated.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41588-022-01282-x>.

## References

- Liu, M. et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat. Genet.* **51**, 237–244 (2019).
- Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**, 290–299 (2021).
- Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide association studies. *Nat. Genet.* **48**, 245–252 (2016).
- Nagpal, S. et al. TIGAR: an improved bayesian tool for transcriptomic data imputation enhances gene mapping of complex traits. *Am. J. Hum. Genet.* **105**, 258–266 (2019).
- Gamazon, E. R. et al. A gene-based association method for mapping traits using reference transcriptome data. *Nat. Genet.* **47**, 1091–1098 (2015).
- Hu, Y. et al. A statistical framework for cross-tissue transcriptome-wide association analysis. *Nat. Genet.* **51**, 568–576 (2019).
- Gusev, A. et al. Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. *Nat. Genet.* **50**, 538–548 (2018).
- Wu, L. et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nat. Genet.* **50**, 968–978 (2018).
- Hall, L. S. et al. A transcriptome-wide association study implicates specific pre- and post-synaptic abnormalities in schizophrenia. *Hum. Mol. Genet.* **29**, 159–167 (2020).
- Bhattacharya, A. et al. A framework for transcriptome-wide association studies in breast cancer in diverse study populations. *Genome Biol.* **21**, 42 (2020).
- Peterson, R. E. et al. Genome-wide association studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommendations. *Cell* **179**, 589–603 (2019).
- Lam, M. et al. Comparative genetic architectures of schizophrenia in East Asian and European populations. *Nat. Genet.* **51**, 1670–1678 (2019).
- Marigorta, U. M. & Navarro, A. High trans-ethnic replicability of GWAS results implies common causal variants. *PLoS Genet.* **9**, e1003566 (2013).
- Liu, Y. & Xie, J. Cauchy combination test: a powerful test with analytic p-value calculation under arbitrary dependency structures. *J. Am. Stat. Assoc.* **115**, 393–402 (2020).
- de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).
- Qian, W. et al. Brain gray matter volume and functional connectivity are associated with smoking cessation outcomes. *Front. Hum. Neurosci.* **13**, 361 (2019).
- Miquel, M., Toledo, R., García, L. I., Coria-Avila, G. A. & Manzo, J. Why should we keep the cerebellum in mind when thinking about addiction? *Curr. Drug Abuse Rev.* **2**, 26–40 (2009).
- Gil-Miravet, I., Guarque-Chabrera, J., Carbo-Gas, M., Olucha-Bordonau, F. & Miquel, M. The role of the cerebellum in drug-cue associative memory: functional interactions with the medial prefrontal cortex. *Eur. J. Neurosci.* **50**, 2613–2622 (2019).
- Klein, A. P., Ulmer, J. L., Quinet, S. A., Mathews, V. & Mark, L. P. Nonmotor functions of the cerebellum: an introduction. *AJNR Am. J. Neuroradiol.* **37**, 1005–1009 (2016).
- D'Angelo, E. The cerebellum gets social. *Science* **363**, 229 (2019).
- Moulton, E. A., Elman, I., Becerra, L. R., Goldstein, R. Z. & Borsook, D. The cerebellum and addiction: insights gained from neuroimaging research. *Addict. Biol.* **19**, 317–331 (2014).
- Quach, B. C. et al. Expanding the genetic architecture of nicotine dependence and its shared genetics with multiple traits. *Nat. Commun.* **11**, 5562 (2020).
- Supek, F., Bosnjak, M., Skunca, N. & Smuc, T. REVIGO summarizes and visualizes long lists of gene ontology terms. *PLoS ONE* **6**, e21800 (2011).
- Buydens-Branchey, L. & Branchey, M. Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers. *Psychiatry Res.* **157**, 95–104 (2008).
- Criscitelli, K. & Avena, N. M. The neurobiological and behavioral overlaps of nicotine and food addiction. *Prev. Med.* **92**, 82–89 (2016).
- Bryois, J. et al. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease. *Nat. Genet.* **52**, 482–493 (2020).
- Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res.* **46**, D1074–D1082 (2018).
- McClure, E. A., Gipson, C. D., Malcolm, R. J., Kalivas, P. W. & Gray, K. M. Potential role of N-acetylcysteine in the management of substance use disorders. *CNS Drugs* **28**, 95–106 (2014).
- Aubin, H. J., Luquiens, A. & Berlin, I. Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. *Br. J. Clin. Pharm.* **77**, 324–336 (2014).
- Douaihy, A. B., Kelly, T. M. & Sullivan, C. Medications for substance use disorders. *Soc. Work Public Health* **28**, 264–278 (2013).
- Cahill, K., Stevens, S., Perera, R. & Lancaster, T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev.* CD009329 (2013).
- Davis J. *AXS-05 Phase II Trial on Smoking Behavior* (NIH U.S. National Library of Medicine, 2019); <https://ClinicalTrials.gov/show/NCT03471767>



33. Rose J. E. *Proof-of-Concept Investigation with a Aeuosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate* (NIH U.S. National Library of Medicine, 2014); <https://ClinicalTrials.gov/show/NCT01857531>
34. MacLean, R. R., Waters, A. J., Brede, E. & Sofuoglu, M. Effects of galantamine on smoking behavior and cognitive performance in treatment-seeking smokers prior to a quit attempt. *Hum. Psychopharmacol.* **33**, e2665 (2018).
35. Green, E. D. et al. Strategic vision for improving human health at the forefront of genomics. *Nature* **586**, 683–692 (2020).
36. Magi, R. et al. Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. *Hum. Mol. Genet.* **26**, 3639–3650 (2017).
37. Novembre, J. et al. Genes mirror geography within Europe. *Nature* **456**, 98–101 (2008).
38. Tang, S. et al. Novel variance-component TWAS method for studying complex human diseases with applications to Alzheimer's dementia. *PLoS Genet.* **17**, e1009482 (2021).
39. Lee, S., Teslovich, T. M., Boehnke, M. & Lin, X. General framework for meta-analysis of rare variants in sequencing association studies. *Am. J. Hum. Genet.* **93**, 42–53 (2013).
40. Bhattacharya, A. et al. Best practices for multi-ancestry, meta-analytic transcriptome-wide association studies: lessons from the Global Biobank Meta-analysis Initiative. *Cell Genom.* **2**, 100180 (2022).
41. Levin, E. D., Wells, C., Slade, S. & Rezvani, A. H. Mutually augmenting interactions of dextromethorphan and sazetidine-A for reducing nicotine self-administration in rats. *Pharmacol. Biochem. Behav.* **166**, 42–47 (2018).
42. Sofuoglu, M., Herman, A. I., Li, Y. & Waters, A. J. Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report. *Psychopharmacology* **224**, 413–420 (2012).
43. Mowinckel, A. M. & Vidal-Piñeiro, D. Visualization of brain statistics with R packages ggseg and ggseg3d. *Adv. Methods Pract. Psychol. Sci.* **3**, 466–483 (2020).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

**Fang Chen**<sup>1,68</sup>, **Xingyan Wang**<sup>1,68</sup>, **Seon-Kyeong Jang**<sup>2,68</sup>, **Bryan C. Quach**<sup>3</sup>, **J. Dylan Weissenkampen**<sup>4,5</sup>, **Chachrit Khunsriraksakul**<sup>6</sup>, **Lina Yang**<sup>1</sup>, **Renan Sauteraud**<sup>1</sup>, **Christine M. Albert**<sup>7,8</sup>, **Nichollette D. D. Allred**<sup>9</sup>, **Donna K. Arnett**<sup>10</sup>, **Allison E. Ashley-Koch**<sup>11,12,13</sup>, **Kathleen C. Barnes**<sup>14</sup>, **R. Graham Barr**<sup>15</sup>, **Diane M. Becker**<sup>16</sup>, **Lawrence F. Bielak**<sup>17</sup>, **Joshua C. Bis**<sup>18</sup>, **John Blangero**<sup>19,20</sup>, **Meher Preethi Boorgula**<sup>14</sup>, **Daniel I. Chasman**<sup>8,21</sup>, **Sameer Chavan**<sup>14</sup>, **Yii-Der I. Chen**<sup>22</sup>, **Lee-Ming Chuang**<sup>23</sup>, **Adolfo Correa**<sup>24</sup>, **Joanne E. Curran**<sup>19,20</sup>, **Sean P. David**<sup>25,26</sup>, **Lisa de las Fuentes**<sup>27</sup>, **Ranjan Deka**<sup>28</sup>, **Ravindranath Duggirala**<sup>19,20</sup>, **Jessica D. Faul**<sup>29</sup>, **Melanie E. Garrett**<sup>11,12</sup>, **Sina A. Gharib**<sup>30,18</sup>, **Xiuqing Guo**<sup>22</sup>, **Michael E. Hall**<sup>31</sup>, **Nicola L. Hawley**<sup>32</sup>, **Jiang He**<sup>33</sup>, **Brian D. Hobbs**<sup>21,34,35</sup>, **John E. Hokanson**<sup>36</sup>, **Chao A. Hsiung**<sup>37</sup>, **Shih-Jen Hwang**<sup>38,39</sup>, **Thomas M. Hyde**<sup>40,41,42</sup>, **Marguerite R. Irvin**<sup>43</sup>, **Andrew E. Jaffe**<sup>40,41,44,45</sup>, **Eric O. Johnson**<sup>3</sup>, **Robert Kaplan**<sup>46,47</sup>, **Sharon L. R. Kardia**<sup>17</sup>, **Joel D. Kaufman**<sup>48</sup>, **Tanika N. Kelly**<sup>33</sup>, **Joel E. Kleinman**<sup>40,41</sup>, **Charles Kooperberg**<sup>49</sup>, **I-Te Lee**<sup>50</sup>, **Daniel Levy**<sup>38</sup>, **Sharon M. Lutz**<sup>51</sup>, **Ani W. Manichaikul**<sup>52</sup>, **Lisa W. Martin**<sup>53</sup>, **Olivia Marx**<sup>54</sup>, **Stephen T. McGarvey**<sup>55</sup>, **Ryan L. Minster**<sup>56</sup>, **Matthew Moll**<sup>34,35</sup>, **Karine A. Moussa**<sup>57</sup>, **Take Naseri**<sup>58</sup>, **Kari E. North**<sup>59</sup>, **Elizabeth C. Oelsner**<sup>15</sup>, **Juan M. Peralta**<sup>19,20</sup>, **Patricia A. Peyser**<sup>17</sup>, **Bruce M. Psaty**<sup>18,60,61</sup>, **Nicholas Rafaels**<sup>14</sup>, **Laura M. Raffield**<sup>62</sup>, **Muagututi'a Sefuiva Reupena**<sup>63</sup>, **Stephen S. Rich**<sup>52</sup>, **Jerome I. Rotter**<sup>22</sup>, **David A. Schwartz**<sup>64</sup>, **Aladdin H. Shadyab**<sup>65</sup>, **Wayne H-H. Sheu**<sup>66</sup>, **Mario Sims**<sup>31</sup>, **Jennifer A. Smith**<sup>17,29</sup>, **Xiao Sun**<sup>33</sup>, **Kent D. Taylor**<sup>22</sup>, **Marilyn J. Telen**<sup>12</sup>, **Harold Watson**<sup>67</sup>, **Daniel E. Weeks**<sup>56</sup>, **David R. Weir**<sup>29</sup>, **Lisa R. Yanek**<sup>16</sup>, **Kendra A. Young**<sup>36</sup>, **Kristin L. Young**<sup>59</sup>, **Wei Zhao**<sup>17,29</sup>, **Dana B. Hancock**<sup>3</sup>, **Bibo Jiang**<sup>1,69</sup>✉, **Scott Vrieze**<sup>2,69</sup>✉ & **Dajiang J. Liu**<sup>1,69</sup>✉

<sup>1</sup>Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA. <sup>2</sup>Department of Psychology, University of Minnesota, Minneapolis, MN, USA. <sup>3</sup>RTI International, Research Triangle, NC, USA. <sup>4</sup>Department of Genetics, University of Pennsylvania, Philadelphia, PA, USA. <sup>5</sup>Department of Psychology, Penn State College of Medicine, Hershey, PA, USA. <sup>6</sup>Department of Bioinformatics and Genomics, Penn State College of Medicine, Hershey, PA, USA. <sup>7</sup>Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. <sup>8</sup>Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA. <sup>9</sup>Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA. <sup>10</sup>College of Public Health, University of Kentucky, Lexington, KY, USA. <sup>11</sup>Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC, USA. <sup>12</sup>Department of Medicine, Duke University Medical Center, Durham, NC, USA. <sup>13</sup>Duke Comprehensive Sickle Cell Center, Duke University Medical Center, Durham, NC, USA. <sup>14</sup>Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Center, Aurora, CO, USA. <sup>15</sup>Department of Medicine, Columbia University Medical Center, New York, NY, USA. <sup>16</sup>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. <sup>17</sup>Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA. <sup>18</sup>Department of Medicine, Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA. <sup>19</sup>Department of Human Genetics, University of Texas Rio Grande Valley School of Medicine,

Brownsville, TX, USA. <sup>20</sup>South Texas Diabetes and Obesity Institute, University of Texas Rio Grande Valley School of Medicine, Brownsville, TX, USA. <sup>21</sup>Harvard Medical School, Boston, MA, USA. <sup>22</sup>Department of Pediatrics, Institute for Translational Genomics and Population Sciences, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA. <sup>23</sup>Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. <sup>24</sup>Department of Medicine, Jackson Heart Study, University of Mississippi Medical Center, Jackson, MS, USA. <sup>25</sup>University of Chicago, Chicago, IL, USA. <sup>26</sup>NorthShore University Health System, Evanston, IL, USA. <sup>27</sup>Department of Medicine, Division of Biostatistics and Cardiovascular Division, Washington University School of Medicine, St. Louis, MO, USA. <sup>28</sup>Department of Environmental and Public Health Sciences, College of Medicine, University of Cincinnati, Cincinnati, OH, USA. <sup>29</sup>Institute for Social Research, Survey Research Center, University of Michigan, Ann Arbor, MI, USA. <sup>30</sup>Computational Medicine Core at Center for Lung Biology, Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle, WA, USA. <sup>31</sup>Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA. <sup>32</sup>Department of Epidemiology (Chronic Disease), School of Public Health, Yale University, New Haven, CT, USA. <sup>33</sup>Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA. <sup>34</sup>Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA. <sup>35</sup>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA. <sup>36</sup>Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. <sup>37</sup>Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan. <sup>38</sup>The Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. <sup>39</sup>The Framingham Heart Study, Framingham, MA, USA. <sup>40</sup>Lieber Institute for Brain Development, Baltimore, MD, USA. <sup>41</sup>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. <sup>42</sup>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. <sup>43</sup>Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA. <sup>44</sup>Department of Mental Health and Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. <sup>45</sup>Department of Human Genetics and Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA. <sup>46</sup>Department of Epidemiology and Population Health, Albert Einstein College of Medicine, The Bronx, NY, USA. <sup>47</sup>Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. <sup>48</sup>Departments of Environmental & Occupational Health Sciences, Medicine, and Epidemiology, University of Washington Seattle, Seattle, WA, USA. <sup>49</sup>Fred Hutchinson Cancer Center, Seattle, WA, USA. <sup>50</sup>Department of Internal Medicine, Division of Endocrinology and Metabolism, Taichung Veterans General Hospital, Taichung, Taiwan. <sup>51</sup>Department of Population Medicine, Harvard Pilgrim Health Care, Boston, MA, USA. <sup>52</sup>Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA. <sup>53</sup>Division of Cardiology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA. <sup>54</sup>Department of Biomedical Sciences, Penn State College of Medicine, Hershey, PA, USA. <sup>55</sup>Department of Epidemiology, International Health Institute, Brown University School of Public Health, Providence, RI, USA. <sup>56</sup>Department of Human Genetics and Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA. <sup>57</sup>Penn State Huck Institutes of Life Sciences, Penn State College of Medicine, University Park, PA, USA. <sup>58</sup>Ministry of Health, Government of Samoa, Apia, Samoa. <sup>59</sup>Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. <sup>60</sup>Department of Epidemiology, University of Washington, Seattle, WA, USA. <sup>61</sup>Department of Health Systems and Population Health, University of Washington, Seattle, WA, USA. <sup>62</sup>Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. <sup>63</sup>Lutia I Puava Ae Mapu I Fagalele, Apia, Samoa. <sup>64</sup>Department of Medicine, University of Colorado, Aurora, CO, USA. <sup>65</sup>Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA. <sup>66</sup>Taipei Veterans General Hospital, Taipei, Taiwan. <sup>67</sup>Faculty of Medical Sciences, University of the West Indies, Cave Hill Campus, Barbados. <sup>68</sup>These authors contributed equally: Fang Chen, Xingyan Wang, Seon-Kyeong Jang. <sup>69</sup>These authors jointly supervised this work: Bibo Jiang, Scott Vrieze, Dajiang J. Liu. ✉ e-mail: [bjiang@phs.psu.edu](mailto:bjiang@phs.psu.edu); [vrieze@umn.edu](mailto:vrieze@umn.edu); [dajiang.liu@psu.edu](mailto:dajiang.liu@psu.edu)

## Methods

In this section, we describe the smoking phenotype definition, the summary association statistics from the GSCAN and TOPMed consortium, as well as the TESLA method. The enrichment and drug-repurposing analyses are described in Supplementary Text. The detailed descriptions of transcriptomics datasets from the GTEx consortium, LIBD Human Brain Repository and mouse scRNA-seq data can also be found in Supplementary Text.

### Phenotype definition

We analyzed the following four smoking behavior-related traits because of their broad availability in existing epidemiological and medical studies, as well as their biological relevance to addiction behaviors:

- (1) Smoking initiation (SmkInit): a binary trait that compares ever smokers with never smokers. Ever smokers were defined as individuals who have smoked >99 cigarettes in their lifetime, which is consistent with the definition by the Center for Disease Control<sup>44</sup>.
- (2) Cigarettes per day (CigDay): a quantitative trait that measures the average number of cigarettes smoked per day by an ever smoker.
- (3) Smoking cessation (SmkCes): a binary trait that compares former against current smokers.
- (4) Age of smoking initiation (AgeInit): a continuous outcome that measures the age when one starts regular smoking.

More detailed definitions for the four phenotypes can be found in Supplementary Text, which is reproduced from our published GSCAN studies<sup>1</sup>.

### GWAS summary association statistics

Our study used GWAS summary association statistics from 61 participating studies as input (Supplementary Table 3). These studies were analyzed using either (generalized) linear models or linear mixed models and adjusted for age, sex and at least ten genetic PCs. The adjusted covariates may differ slightly between studies. All participating studies in the meta-analysis were examined by extensive quality control, including the check of Manhattan plots and quantile–quantile plots. The genomic control values for all participating cohorts are between 0.9 and 1.1 (Supplementary Table 15). We assessed the probability of the meta-analysis results being genuine using MAMBA<sup>45</sup>, a model-based method that relies on the strength of consistency of association signals across studies.

We use  $b_{jk}$  and  $s_{jk}$  to denote the phenotypic effects and standard deviation for variant  $j$  in study  $k$ . We further use  $z_{jk} = b_{jk}/s_{jk}$  to denote the  $z$ -score statistic. In our analysis, standardized genotypes (that is, when genotypes are normalized to have mean 0 and variance of 1) are used, so that the standard deviation  $s_{jk}$  is inversely proportional to  $\sqrt{n_{jk}}$ , that is,  $z_{jk} \approx \sqrt{n_{jk}}b_{jk}$ . The results could be easily extended when non-standardized genotypes were used. In sequence-based genetic studies, score statistics are often generated, from which we can derive approximate phenotypic effects using the above formula. The approximation is known to be accurate if true phenotypic effects are small<sup>46</sup>.

In addition to phenotypic effects and their standard deviations, we also take the PCs (or multi-dimensional scaling coefficients<sup>36</sup>) of the cohort allele frequencies as input, which serve as proxies for the cohort ancestry (Supplementary Fig. 4). Allele frequencies from different ancestry groups show systematic differences, which can be captured by the PCs.

### Proportionality condition for optimal TWAS power

We derived conditions for the TWAS statistic to have optimal power and used them to explain why direct integration of eQTL data with GWASs from different ancestries leads to suboptimal TWASs. We then proposed new and improved TWAS methods for integrating trans-ancestry GWASs with European eQTL datasets.

TWASs (and similar methods) were proposed to integrate eQTL effects with GWASs, to identify transcripts/genes that are associated with phenotypes. The TWAS statistic is often written in the form of a linear combination of  $z$ -score statistics (which is proportional to phenotypic effect estimates when standardized genotypes are used):

$$U_{\text{TWAS}} = \sum_j w_j z_j \quad (1)$$

where  $w_j$  are the weights obtained from a gene expression prediction model. The variance for the statistic  $U_{\text{TWAS}}$  equals:

$$V_{\text{TWAS}} = \mathbf{w}' V_z \mathbf{w} \quad (2)$$

where  $\mathbf{w}$  is the vector of eQTL weights trained from gene expression prediction models, that is,  $\mathbf{w} = (w_1, \dots, w_j)$  with  $J$  being the total number of variants used in the prediction model.  $V_z$  is the covariance matrix between  $z$ -score statistics, which can be approximated based on reference panels.

It is well understood that the choice of the weights can affect the power for the statistic  $U_{\text{TWAS}}$ . To attain optimal power, the weights have to be chosen to maximize the noncentrality parameter of the test statistic, that is,  $\mu_{\text{TWAS}}^2 = (E(U_{\text{TWAS}}/\sqrt{V_{\text{TWAS}}}))^2$ . Applying Cauchy Schwarz inequality, a given set of eQTL weights yields the optimal power if they are proportional to the phenotypic effects, that is  $w_j \propto \beta_j$ . We call this the 'proportionality condition'.

In TWAS methods, the eQTL effects are used as weights to combine phenotypic effect estimates of GWASs from the same ancestry. If the phenotypic effects are mediated by the eQTL effects, that is,  $G_j \xrightarrow{w_j} E \xrightarrow{c} Y$ , and the phenotypic and eQTL effects are homogeneous in samples from the same ancestry, the weights and phenotypic effects will satisfy the proportionality condition, that is,  $\beta_j = w_j c$ , and TWAS will yield optimal power as a gene-level test.

### Improved TWASs in trans-ancestry genetic studies

In contrast to TWASs using European GWASs and eQTL datasets, measured phenotypic effects can differ between ancestries in multi-ancestry genetic studies due to possibly different causal variants, allele frequencies or LD patterns. As a result, the proportionality condition may be violated when the GWAS and eQTL data come from different ancestries. Nor will the proportionality condition hold when FE or RE meta-analysis results from a multi-ancestry study are used with European eQTL dataset for TWASs. Suboptimal power is expected. Alternatively, if a TWAS is performed using European GWAS results and European eQTL dataset, and if the phenotypic effects and eQTL effects are homogeneous in the European population, the proportionality condition is expected to hold. Yet this strategy leaves out non-European GWAS data in the study and can still lead to suboptimal power when causal variants are shared between ancestries<sup>47</sup>.

Leveraging ancestral diversity while accounting for between-ancestry heterogeneities can improve the accuracy of the phenotypic effects in the matched ancestry of the eQTL data. For GWAS cohorts from different ancestries than the eQTL dataset, TESLA projects their phenotypic effects in the direction of eQTL weights, which are then meta-analyzed with other studies to get more accurate phenotypic effect estimates. TESLA uses these improved phenotypic effects to perform TWASs for optimal power.

### Multi-ancestry meta-regression models for phenotypic effects

We model the phenotypic effect estimates of eQTL SNPs of a given gene as a fixed effect of the ancestry captured by the allele frequency PCs. To calculate the PCs of allele frequencies, we code the allele frequency matrix using variant sites shared across all studies as  $F$ , where each row represents a study and each column represents a variant site. We then perform singular value decomposition for  $F$ , that is,  $F = C_r D_r E_r'$ . In our

analyses, we use the first three PCs, which is the first three columns of the matrix  $FE_F$ . We denoted the  $l$ th PCs for study  $k$  as  $X_{kl}$  and the phenotypic effects of multiple genetic variants in study  $k$  as  $b_{.k}$ . For notational convenience, we fix  $X_{k0}$  to 1.

We vary the number of PCs used (that is,  $L$ ) and consider a series of models  $M^{[L]}$ :

$$M^{[L]} : b_{.k} = \sum_{l=0}^L X_{kl} \gamma_l^{[L]} + \epsilon_{.k} \quad (3)$$

where  $b_{.k} = (b_{1k}, \dots, b_{jk})$  is the phenotypic effects of eQTL SNPs 1, ...,  $J$  for the gene and  $\epsilon_{.k} = (\epsilon_{1k}, \dots, \epsilon_{jk})$  is the vector of residuals. The residuals follow multivariate normal distribution.  $\gamma_l^{[L]} = (\gamma_{1l}^{[L]}, \dots, \gamma_{jl}^{[L]})$  are the regression coefficients for variants 1, ...,  $J$ .

In our simulations and data analyses, we considered  $L = 0, 1, 2$  or 3. When no PCs are included in the model, it is equivalent to the FE meta-analysis, which is suitable for modeling variants that have homogeneous effects across studies. When one or more PCs are included in the model, it can capture phenotypic effect heterogeneity between studies.

Under model  $M^{[L]}$ , the phenotypic effect follows a normal distribution:

$$b_{jk|M^{[L]}} \sim N\left(\sum_{l=1}^L X_{kl} \gamma_l^{[L]}, s_{jk}^2\right).$$

Model  $M^{[L]}$  can be fitted using the weighted least square method<sup>36</sup>. The solution satisfies:

$$\hat{\gamma}_j^{[L]} = \left(X^{[L]'} \Omega_j X^{[L]}\right)^{-1} X^{[L]'} \Omega_j b_j. \quad (4)$$

where  $\Omega_j = \text{diag}(s_{j1}, \dots, s_{jK})$ .

Based on meta-regression coefficients, we can estimate phenotypic effects in the ancestry of the eQTL dataset so that the eQTL weights and phenotypic effect estimates satisfy the proportionality condition. The first  $L$  PC coordinates of the eQTL dataset are denoted  $\bar{X}^{[L]}$  and the phenotypic effect estimates in the ancestry of the eQTL dataset are given by:

$$\hat{b}_j^{[L]} = \bar{X}^{[L]} \hat{\gamma}_j^{[L]} = \bar{X}^{[L]} \left(X^{[L]'} \Omega_j X^{[L]}\right)^{-1} X^{[L]'} \Omega_j b_j.$$

We denote the vector of estimated effects as  $\hat{\mathbf{b}}^{[L]} = (\hat{b}_1^{[L]}, \dots, \hat{b}_j^{[L]})$ , the covariance matrix of which is  $\Sigma_{\hat{\mathbf{b}}}^{[L]}$ . To calculate  $\Sigma_{\hat{\mathbf{b}}}^{[L]}$ , we use the fact that the predicted phenotypic effects  $\hat{b}_j^{[L]}$  are a linear combination of the phenotypic effects across all participating studies. As a result, we can calculate the correlation between the predicted effects of variants  $j_1$  and  $j_2$ , that is,  $b_{j_1}^{[L]}$  and  $b_{j_2}^{[L]}$ , based on the correlations between  $b_{j_1k}$  and  $b_{j_2k}$  in each study  $k$ . Given that each cohort may come from different ancestries, we use ancestry-specific reference panels to estimate LD and approximate the correlations between  $b_{j_1k}$  and  $b_{j_2k}$ . Detailed derivation of the covariance matrix can be found in Supplementary Text. The standard deviation for the estimated effects  $\hat{\mathbf{b}}^{[L]}$  is denoted by  $\hat{\mathbf{s}}^{[L]} = (s_1^{[L]}, \dots, s_j^{[L]})$ , which equals the square root of the diagonal entries of  $\Sigma_{\hat{\mathbf{b}}}^{[L]}$ .

### TESLA using predicted phenotypic effect

Based on the phenotypic effect estimate  $\hat{\mathbf{b}}^{[L]}$  and its standard deviation  $\hat{\mathbf{s}}^{[L]}$ , we constructed our TWAS statistic as  $U_{\text{TWAS}}^{[L]} = \sum_{j=1}^L w_j \hat{b}_j^{[L]} / s_j^{[L]}$ . The variance for the statistic equals:

$$V_{\text{TWAS}}^{[L]} = \mathbf{w}' \left(\text{diag}(s_1^{[L]}, \dots, s_j^{[L]})\right)^{-1} \Sigma_{\hat{\mathbf{b}}}^{[L]} \left(\text{diag}(s_1^{[L]}, \dots, s_j^{[L]})\right)^{-1} \mathbf{w} \quad (5)$$

We further calculated the standardized statistic as

$$T_{\text{TWAS}}^{[L]} = U_{\text{TWAS}}^{[L]} / \sqrt{V_{\text{TWAS}}^{[L]}}$$

Four different TWAS statistics are calculated that correspond to the models with 0–3 PCs. The model with 0 PC is equivalent to FE-TWAS. When the same eQTL weights are used in each study, FE-TWAS is also equivalent to conducting TWAS in each participating study and then combining results using inverse-variance, weighted meta-analysis (Supplementary Text).

We use a minimal  $P$ -value approach to find the overall  $P$  value for the statistic. Specifically, we denote the  $P$  values for the four statistics as  $P^{[0]}, \dots, P^{[3]}$ . The minimal  $P$ -value statistic  $P^* = \min(P^{[0]}, \dots, P^{[3]})$  follows:

$$\Pr(P^* < p^*) = 1 - \Pr(P^* > p^*) = 1 - \Pr\left(\Phi^{-1}(1 - p^*) < T_{\text{TWAS}}^{[1]} < \Phi^{-1}(p^*), \dots, \Phi^{-1}(1 - p^*) < T_{\text{TWAS}}^{[4]} < \Phi^{-1}(p^*)\right) \quad (6)$$

which can be evaluated using multivariate normal distribution function. Details can be found in Supplementary Text.

### Multi-tissue TESLA statistic using the Cauchy combination

In addition to the single-tissue TESLA statistic, we also calculated a cross-tissue TWAS statistic. Numerous methods exist to combine  $P$  values from correlated test statistics, from which we chose to use the Cauchy combination<sup>14</sup> due to its excellent power and the ease of calculation. In our analysis, we assigned equal weight to each tissue in the Cauchy combination test.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

We implemented a Shiny app for users to interactively explore research results, which is available at <https://liugroupstatgen.shinyapps.io/shiny-tesla-only>. Precomputed gene expression prediction model weights of 48 tissues are from the PrediXcan website (GTEx v.7): <https://predictdb.org>. GO and pathway gene sets are from MSigDB (<https://www.gsea-msigdb.org/gsea/msigdb>). RNA-seq and genotype data from postmortem nucleus accumbens samples of physiologically normal human brains are from the LIBD Human Brain Repository Data (<http://eqtl.brainseq.org/phase2/eqtl>).

### Code availability

TELSA is implemented in our rare GWAMA software package and made available at GitHub (<https://github.com/funfunchen/rareGWAMA>) and Zenodo (<https://doi.org/10.5281/zenodo.7352120>)<sup>48</sup>. Other software used includes MAGMA (v.1.0.8; <https://ctg.cncr.nl/software/magma>); REVIGO (accessed May 2022; <http://revigo.irb.hr>); METASOFT (v.2.0.1; <http://zarlab.cs.ucla.edu/software>); MAMBA (v.1.12; <https://github.com/danI1mcguire/mamba>); MetaXcan (v.0.7.1; <https://github.com/hakyimlab/MetaXcan>); R Shiny (v.1.7.2; <https://cran.r-project.org/web/packages/shiny/index.html>); and ggseg (v.1.5.3; <https://github.com/ggseg/ggseg>).

### References

- Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2007. *MMWR Morb. Mortal. Wkly Rep.* **57**, 1221–1226 (2008).
- McGuire, D. et al. Model-based assessment of replicability for genome-wide association meta-analysis. *Nat. Commun.* **12**, 1964 (2021).
- Lin, D. Y. & Tang, Z. Z. A general framework for detecting disease associations with rare variants in sequencing studies. *Am. J. Hum. Genet.* **89**, 354–367 (2011).

47. Kichaev, G. & Pasaniuc, B. Leveraging functional-annotation data in trans-ethnic fine-mapping studies. *Am. J. Hum. Genet.* **97**, 260–271 (2015).
48. Chen F. R package for multi-ancestry transcriptome-wide association analysis. *Zenodo* <https://doi.org/10.5281/zenodo.7352120> (2022).

## Acknowledgements

Methodology development and meta-analyses were supported by the National Institutes of Health (NIH) grants (nos. R01HG008983 to D.J.L., R56HG011035 to D.J.L., B.J. and S.V., R01HG011035 to F.C., D.J.L., S.V. and X.W., R56HG012358 to D.J.L., R01GM126479 to D.J.L., R21AI160138 to D.J.L. and R03OD032630 to D.J.L. and B.J.). D.J.L. and X.W. and were in part supported by the Penn State College of Medicine's Biomedical Informatics and Artificial Intelligence Program in the Strategic Plan. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute, the NIH or the US Department of Health and Human Services. Funding acknowledgement for participating cohorts is in Supplementary Text.

## Author contributions

D.J.L., B.J. and S.V. designed, led and oversaw the study. F.C. and X.W. were the study's lead analysts. X.W., D.J.L. and F.C. carried out software development. J.D.W., C. Khunsriraksakul, L.Y., R.S., O.M. and K.A.M. contributed to meta-analyses. S.K.J. generated summary statistics from TOPMed studies and contributed to meta-analyses. B.C.Q., C.M.A., N.D.D.A., D.K.A., A.E.A.K., K.C.B.,

R.G.B., D.M.B., L.F.B., J.C.B., J.B., M.P.B., D.I.C., S.C., Y.D.I.C., L.M.C., A.C., J.E.C., S.P.D., L.F., R. Deka, R. Duggirala, J.D.F., M.E.G., S.A.G., X.G., M.E.H., N.L.H., J.H., B.D.H., J.E.H., C.A.H., S.J.H., T.M.H., M.R.I., A.E.J., E.O.J., R.K., S.L.R.K., J.D.K., T.N.K., J.E.K., C. Kooperberg, I.T.L., D.L., S.M.L., A.W.M., L.W.M., S.T.M.G., R.L.M., M.M., T.N., K.E.N., E.C.O., J.M.P., P.A.P., B.M.P., N.R., L.M.R., M.S.R., S.S.R., J.I.R., D.A.S., A.H.S., W.H.H.S., M.S., J.A.S., X.S., K.D.T., M.J.T., H.W., D.E.W., D.R.W., L.R.Y., K.A.Y., K.L.Y., W.Z. and D.B.H. contributed to datasets for meta-analyses and integrative genomic analysis. All authors contributed to and critically reviewed the manuscript.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41588-022-01282-x>.

**Correspondence and requests for materials** should be addressed to Bibo Jiang, Scott Vrieze or Dajiang J. Liu.

**Peer review information** *Nature Genetics* thanks Jingjing Yang and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

TESLA is implemented and made available in <https://github.com/funfunchen/rareGWAMA> (DOI: 10.5281/zenodo.7352120). Other softwares used included: MAGMA (v1.08, <https://ctg.cncr.nl/software/magma>), REVIGO (accessed 2022/05; <http://revigo.irb.hr/>), CirGO (accessed 2022/05; <https://github.com/IrinaVKuznetsova/CirGO>), METASOFT (v2.0.1; <http://zarlab.cs.ucla.edu/software/>), MetaXcan (v0.7.1; <https://github.com/hakymilab/MetaXcan>), R Shiny (v1.7.2), MAMBA (v1.12; <https://github.com/dan11mcguire/mamba>), ggseg (v1.5.3; <https://github.com/ggseg/ggseg>).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Pre-computed gene expression prediction model weights of 48 tissues are from the PrediXcan website (GTE<sub>x</sub> v7): <https://predictdb.org/>. Gene Ontology (GO) and pathway gene sets are from MSigDB (<https://www.gsea-msigdb.org/gsea/msigdb/>). RNA-seq and genotype data from postmortem nucleus accumbens samples of physiologically normal human brains are from Lieber Institute for Brain Development

(LIBD) Human Brain Repository Data (<http://eqtl.brainseq.org/phase2/eqtl/>).

Single cell RNA-seq data from entire mouse nervous system is from [https://github.com/jbryois/scRNA\\_disease](https://github.com/jbryois/scRNA_disease).

GWAS datasets from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) and the Trans-Omics Precision Medicine (TOPMed).

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	In this study, we conducted a multi-ancestry TWAS using GWAS data from the GSCAN study and whole genome sequence from TOPMed with a total sample size of 1.3 million individuals (1.2 million from the GSCAN and 150,000 from the TOPMed).
Data exclusions	There is no data exclusions in our analysis. All datasets that pass quality controls are analyzed.
Replication	We use MAMBA to assess the GWAS association signals which is a model based method to assess whether the signal is genuine or not without a replication dataset. MAMBA works by examining the strength and consistency of association signals across studies.
Randomization	This is re-analysis of existing datasets coming from observational studies. No new data is collected. No randomization is performed here.
Blinding	This is re-analysis of existing datasets coming from observational studies. No new data is collected. No randomization is performed here.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging